Document is current
Any future updates will be listed below
-
Authors
Zhang, Lina
Liu, Yueping
Yang, Chao
Ma, Jie
Li, Yuntao
Luo, Ruizhen
Han, Jianjun
Wang, Xiaochun
Zhang, Zhisheng
Ma, Li
Cai, Haifeng
Kong, Xiangshun
Wang, Zunyi
Zhou, Xinping
Shi, Jiajie
Zhang, Yanshou
Wang, Meiqi
Wang, Jiaxing
Geng, Cuizhi
-
Funding
Funding for this research was provided by:
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2022ZD-0772)
Jiangsu Hengrui Pharmaceuticals Co., Ltd
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 5 February 2025
First Online: 13 February 2025
Declarations
:
: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). This study was approved by the institutional ethics committee at each site and informed consent was taken from all the patients.
: Not applicable.
: The authors declare no competing interests.
